Collaboration Antigen definition

Collaboration Antigen means, with respect to each Program, the Antigen selected in accordance with Section 4.3; provided, that the Collaboration Antigen shall not be a Cue Reserved Antigen.
Sample 1Sample 2
Collaboration Antigen means any Antigen listed as a “Collaboration Antigen” on Exhibit B, as such Exhibit may be amended pursuant to Sections 2.2.1(j), 2.2.1(l), 2.2.2(c), 2.2.2(d), 2.3.1, 2.3.3, 2.6.4, 2.6.5, 4.15, 5.9, 5.11 and 16.8.3(a).
Sample 1Sample 2
Collaboration Antigen means the Initial Collaboration Antigen, the Second Collaboration Antigen and any other Antigen so designated pursuant to Sections 4.5.2 or 9.7.
Sample 1

Examples of Collaboration Antigen in a sentence

  • For each Collaboration Antigen, during the Research Term for the applicable Research Candidates and following review of the data from activities under the applicable Research Plan, the JSC will select a Research Candidate that specifically targets such Collaboration Antigen to be a Development Candidate for Development pursuant to an Early Clinical Development Program in accordance with the terms and conditions of this Agreement.

  • With respect to each Collaboration Antigen, Unum (itself or through its Affiliates or by permitted subcontracting pursuant to Section 5.9) agrees to use Commercially Reasonable Efforts to Develop Research Candidates in the Territory, and to carry out the tasks specified under the Research Plan, in a timely and effective manner, and agrees to conduct its activities under the Research Plan in a good scientific manner and in compliance in all material respects with Applicable Law.

  • To the extent known to ABX, ABX shall notify AZ of any such risks with respect to an Antigen prior to its designation as a Proposed Antigen, Prioritized Antigen or Collaboration Antigen, whichever is earlier.

  • Unless otherwise specified in this Agreement, this Article 7 governs the procedures and the Parties’ rights and obligations with respect to forecasts, purchase orders and delivery for Collaboration Antigen Product to applicable Product Requirements.

  • The written notice on the closing date or effective date of such Change in Control or Acquisition, whichever is later, shall include a written list of any Competitive Product with respect to a Collaboration Antigen or Prioritized Antigen.

  • Unless otherwise agreed by AZ, such additional activities with respect to a Collaboration Antigen shall be performed by ABX (provided that, unless ABX otherwise consents in writing, all such additional work for all Collaboration Antigens does not exceed [Confidential treatment requested] additional FTEs in the aggregate for each year).

  • If AZ determines that it is safe for AZ or its sublicensees to pursue the research, development, launch or sale of such Licensed Product in such Major Market(s), then AZ shall have the right to elect not to terminate this Agreement with respect to such Collaboration Antigen and instead continue to Exploit such Licensed Product pursuant to this Agreement.

  • If AZ declines to designate such Antigen as a Collaboration Antigen, AZ shall notify ABX in writing and, if ABX wishes to pursue Antibodies or Antibody Equivalents that bind to and are directed against such Antigen, ABX shall provide an Exercise Notice to AZ and such Antigen shall be designated a Discontinued Antigen, but only with respect to those Antibodies that have been offered to AZ either before such Antigen was designated a Failed Antigen or during such [Confidential treatment requested] period.

  • Except as provided in Section 5.7, all INDs and other filings, applications or requests for Candidate Drugs pursuant to or in connection with the Registrations and other regulatory documentation shall be owned by and made in the name of AZ or its designee(s), and AZ shall have the sole right to conduct all communications with the regulatory authorities with regard to the Candidate Drugs and AZ Products with respect to a Collaboration Antigen.

  • Promptly following the designation of an Antigen as a Collaboration Antigen, the Parties shall negotiate in good faith to determine the financial terms on which the license grant to AZ under clause (ii) above shall be made.


More Definitions of Collaboration Antigen

Collaboration Antigen means each of (i) a human papillomavirus (“HPV”) antigen and (ii) each other Antigen mutually selected by the Parties. For the avoidance of doubt, TCL is not a Collaboration Antigen.
Sample 1

Related to Collaboration Antigen

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Collaboration Product means any pharmaceutical product in finished form that contains a Collaboration Compound, either as the sole active ingredient or in combination with one or more other active ingredients, and all present and future formulations, dosages and dosage forms thereof.

  • Licensed Compound means [***].

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Licensed Compounds means any EZH2 Compound(s) that is:

  • Collaboration Know-How means all Know-How and Materials discovered, created, conceived, developed or reduced to practice in the course of performing activities under the Collaboration Program (whether solely by one Party or jointly by the Parties, in each case with their Affiliates or any Third Parties or any employees, consultants or agents of any of the foregoing which perform activities under the Collaboration Program).

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Antigen means a substance recognized by the body as being foreign; it results in the production of specific antibodies directed against it.

  • Collaboration IP means Collaboration Know-How and Collaboration Patents.

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.

  • Research Program has the meaning set forth in Section 2.1.

  • Collaboration Term has the meaning specified in Section 2.1.2 hereof.

  • Research Program Term has the meaning set forth in Section 2.2.

  • Collaboration Patents means any and all Patents that claim or cover any of the Collaboration Know-How.

  • Collaboration has the meaning set forth in Section 2.1.

  • Research Plan shall have the meaning set forth in Section 2.1.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Collaboration Technology means all Collaboration Patents and Collaboration Know-How.

  • Collaborator An individual who is not under the direct supervision of the PI (e.g., not a member of the PI’s laboratory) who assists with the PI’s research project involving controlled-access data subject to the NIH GDS Policy. Internal collaborators are employees of the Requester and work at the same location/campus as the PI. External collaborators are not employees of the Requester and/or do not work at the same location as the PI, and consequently must be independently approved to access controlled-access data subject to the NIH GDS Policy.

  • Commercialization or “Commercialize” means any and all activities undertaken at any time for a particular Licensed Product and that relate to the manufacturing, marketing, promoting, distributing, importing or exporting for sale, offering for sale, and selling of the Licensed Product, and interacting with Regulatory Authorities regarding the foregoing.

  • Development Program means the implementation of the development plan.